1. Home
  2. EPSM vs SKYE Comparison

EPSM vs SKYE Comparison

Compare EPSM & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPSM

Epsium Enterprise Limited Ordinary Shares

N/A

Current Price

$2.33

Market Cap

51.6M

Sector

N/A

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

N/A

Current Price

$1.06

Market Cap

44.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EPSM
SKYE
Founded
2010
2012
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.6M
44.9M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
EPSM
SKYE
Price
$2.33
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.75
AVG Volume (30 Days)
2.1M
249.9K
Earning Date
12-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,446,963.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$1.02
52 Week High
$155.00
$5.75

Technical Indicators

Market Signals
Indicator
EPSM
SKYE
Relative Strength Index (RSI) 31.60 36.45
Support Level $2.20 $1.04
Resistance Level $4.00 $1.27
Average True Range (ATR) 0.37 0.09
MACD 0.56 0.02
Stochastic Oscillator 8.65 5.88

Price Performance

Historical Comparison
EPSM
SKYE

About EPSM Epsium Enterprise Limited Ordinary Shares

Epsium Enterprise Ltd is a holding company and conducts business through its subsidiaries. It is engaged in import trading and wholesale selling of beverages in Macau. The company imports and sells a range of beverages, alcoholic beverages, and a small quantity of tea and fruit juice. The alcoholic beverages it sells include Chinese liquor, French cognac, Scottish whiskey, fine wine, Champagne, and other miscellaneous beverage alcohol.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: